21 year-old channel four intern Corrnelius began losing his vision during his A-Levels, discover how assistive tech helped him develop the gift of the gab: https://www.fightforsight.org.uk//cornelius-story

#LHON #VisionLoss #Education #LivingWithVisionLoss

Nitric Oxide May Adversely Affect the Metabolism and Viability of Retinal Organoids Derived from Patients with Leber Hereditary Optic Neuropathy Leber hereditary optic neuropathy (LHON) is a bilateral optic neuropathy associated with mitochondrial DNA (mtDNA) mutations characterized by parapapillary telangiectasia during the acute phase. Howev...

In @ajpathology.bsky.social, Takano et al. find that nitric oxide may drive retinal cell death in Leber hereditary optic neuropathy patient–derived #organoids. It also disrupts their metabolic profiles.

ajp.amjpathol.org/article/S000...

🧪 🧬 #ophthosky #LHON

From Castro to Quantum Mechanics: Marching Through Tunnels With Reactive Oxygen Species: Journal of Neuro-Ophthalmology
Article: bit.ly/JNO_LHON_Cuba
#brain #eye #vision #research #Neurology #NeuroOphth #Ophthalmology #Medicine #LHON Doheny Eye Institute

Metformin promotes mitochondrial integrity through AMPK-signaling in Leber's hereditary optic neuropathy

👉 buff.ly/1dLZgUl

#Metformin #Mitochondria #LHON #Lebers

👁 The FDA has granted Priority Review to idebenone (Raxone) for LHON, with a decision expected by Feb 28, 2026. If approved, it would be the first FDA-approved therapy for this rare eye disease in the US.

Details: ophthalmologymanagem...

#LHON #FDA #Ophthalmology

Chiesi scores FDA priority review for rare vision disorder Raxone is approved for Leber Hereditary Optic Neuropathy (LHON), a rapid vision-loss disease, in multiple countries, including the EU.

🚨 The FDA has granted Priority Review to Chiesi's Raxone (idebenone), a potential first treatment for Leber Hereditary Optic Neuropathy (LHON), a rare disease causing sudden vision loss. Decision expected by Feb 2026.

#News #RareDisease #Ophthalmology #FDA #LHON #VisionResearch #DrugDevelopment

Chiesi scores FDA priority review for rare vision disorder Raxone is approved for Leber Hereditary Optic Neuropathy (LHON), a rapid vision-loss disease, in multiple countries, including the EU.

🚨 The FDA has granted Priority Review to Chiesi's Raxone (idebenone), a potential first treatment for Leber Hereditary Optic Neuropathy (LHON), a rare disease causing sudden vision loss. Decision expected by Feb 2026.

#News #RareDisease #Ophthalmology #FDA #LHON #VisionResearch #DrugDevelopment

Treatment for cause of sudden sight loss now available through the NHS in England - Moorfields Eye Hospital

A discussion about the approval of idebenone for #LHON from the patients’ perspective: www.moorfields.nhs.uk/about-us/new... @moorfieldsbrc.bsky.social @moorfields.bsky.social

Hundreds of people set to receive the first-ever treatment licensed across Great Britain for the rare mitochondrial eye disease LHON.
Grace Woolston writes more in BioNews: www.progress.org.uk/treatment-fo...

#NICE #LHON #Mitochondria #raredisease #genomics #genetics #DNA

UK NICE recommends Chiesi’s rare eye therapy The final draft guidance supports Chiesi’s Raxone for patients aged 12 and above with Leber Hereditary Optic Neuropathy (LHON).

NICE has issued final draft guidance recommending Chiesi’s Raxone (idebenone) for eligible patients aged 12 and above, marking the first NHS-funded treatment for this rare vision-loss condition in England.

#News #NICE #LHON #RareDisease #VisionHealth #Ophthalmology #PatientAccess #NHS #MedicalNews

UK NICE recommends Chiesi’s rare eye therapy The final draft guidance supports Chiesi’s Raxone for patients aged 12 and above with Leber Hereditary Optic Neuropathy (LHON).

NICE has issued final draft guidance recommending Chiesi’s Raxone (idebenone) for eligible patients aged 12 and above, marking the first NHS-funded treatment for this rare vision-loss condition in England.

#News #NICE #LHON #RareDisease #VisionHealth #Ophthalmology #PatientAccess #NHS #MedicalNews

England poised to roll out drug for rare eye disease LHON Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.

#Ophthalmology #eyedisease #LHON #Lebershereditaryopticneuropathy #mitochondrialgeneticdisorder #Chiesi #Raxone #idebenone #NICE #NICEfinaldraftguidance #centralvisionloss #visionloss #LHONgenes #LHONSociety #mitochondrialDNA #mtDNA #RHODOStrial #LEROStrail #PAROStrial
zurl.co/W87n3

Announcement graphic from NIHR Moorfields Biomedical Research Centre. The top section features a dark blue background with white text stating 'NHS England approves first-ever mitochondrial disease treatment.' To the right, there's an aerial-style illustration of the UK and Ireland at night, with glowing city lights and network lines suggesting connectivity. The NIHR Moorfields logo appears in the top left. The bottom section has a white background with red italicized text reading 'Read our latest news item.

NHS England approves Idebenone (Raxone) to treat Leber’s Hereditary Optic Neuropathy, a rare genetic disease that can lead to sudden vision loss.

🔗 buff.ly/o45O7bu

#NIHRsupported #RareDisease #LHON
@ucleye.bsky.social @moorfields.bsky.social @lilyfoundation.bsky.social @cambridgebrc.bsky.social

Leber Hereditary Optic Neuropath (LHON) is a rare mitochondrial disorder that primarily causes painless, subacute loss of central vision, often leading to legal blindness.

Learn more at LHON.org or umdf.org/lhon/ #lhon

You may be rare, but you are not alone!
#rareDisease #rareDiseaseAwareness

레버 유전성 시신경병증: 젊은 남성을 위협하는 시력 상실 1. 레버 유전성 시신경병증의 정의와 원인레버 유전성 시신경병증(LHON)은 주로 젊은 남성에게 영향을 미치는 유전적 질환으로, 시신경의 손상으로 인해 시력 상실이 발생하는 질환입니다. 이 질환은 주로 미토콘드리아 DNA의 변이에 의해 발생하며, 가장 흔한 변이는 11778G>A, 3460G>A, 14484T>C입니다. 이러한 변이는 시신경의 신경세포에 영...

안녕하세요! 레버 유전성 시신경병증이라는 질병을 가져왔는데요! 한번씩 읽어보세용~

wntjd1004.com/entry/%EB%A0...

#lhon #레버유전성시신경병증 #미토콘드리아 #시력상실
#시신경병증 #안과건강 #유전자치료 #유전질환 #환자지원 #희귀질환

Oliver Simon beschäftigt sich seit Langem mit der Frage: Was heißt „gut mit Blindheit“ leben? Als Mobilitätstrainer begleitet er Seheingeschränkte und Blinde und erweitert so deren Möglichkeiten, sich im Alltag zu bewegen.

#lhon #lhonawareness #podcast #moderator #rarediseases #selteneerkrankung

New gene therapy trial to help restore sight | Cambridge ... A team from Addenbrooke's Hospital in Cambridge is leadin...

New gene therapy trial to help restore sight www.cambridgenetwork.co.uk/news/new-gene-therapy-tr... #LHON, Leber Hereditary Optic Neuropathy